About the difficuties of the diagnostics and treament of the Klatskin`s tumour
https://doi.org/10.29039/1992-6499-2023-2-110-119
Abstract
The relevance of the topic is caused by the insufficient acquaintance of Klatskin's tumor, or the portal cholangiocarcinoma, among the general practitioners, because of the evident rarity of the disease and poor information available for the practical doctors, especially internists, upon the modern opportunities of its clinical manifestations, differential diagnosis and methods of treatment of this pathology. Clinical observation of the portal cholangiocarcinoma at the man of 66 years old is described from the moment of the first complaints/ The difficulties at establishment of the final diagnosis, with the description of modern laboratory toolinstrumental methods of medical visualization, the technics of medical interventions and chemotherapy are represented. A clinical case of this disease is presented.
About the Authors
A. V. Dedov
Astrakhan State Medical University
Russian Federation
Russian Federation
A.V. Dedov, Cand. Sci (Med.), Associate Professor, Associate Professor of Department
Astrakhan
R. D. Mustafin
Astrakhan State Medical University
Russian Federation
Russian Federation
R.D. Mustafin, Dr. Sci (Med.), Professor, Head of the Department
Astrakhan
E. A. Polukhina
Astrakhan State Medical University
Russian Federation
Russian Federation
E.A. Polukhina, 3rd year student of the Faculty of Medicine
Astrakhan
References
1. Everhart J. E., and Ruhl C. E. Burden of digestive diseases in the United States part III: liver, biliary tract, and pancreas. Gastroenterology. 2009; 136 (4): 1134-1144.
2. Klatskin G. Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatis. An unusual tu-mor with distinctive clinical and pathological features. The American Journal of Medicine. 1965; 38 (2): 241-256.
3. Prohorov A. V., Papok V. E. Tumor Klatskin: teaching aid. Minsk: Belarusian State Medical University; 2015. 16 p. (In Russ.).
4. Bergquist A., von Seth E. Epidemiology of cholangiocarcinoma. Best Practice & Research Clinical Gastroen-terology. 2015; 29 (2): 221-232.
5. Khan S. A., Davidson B. R., Goldin R. D., Heaton N., Karani J., Pereira S. P., Rosenberg W. M., Tait P., Tay-lor-Robinson S. D., Thillainayagam A. V., Thomas H. C., Wasan H. British Society of Gastroenterology. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut. 2012; 61 (12): 1657-1669.
6. Valle J. W., Borbath I., Khan S. A., Huguet F., Gruenberger T., Arnold D.; ESMO Guidelines Committee. Bili-ary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2016; 27 (5): 28-37.
7. Associazione Italiana di Oncologia Medica. I Dati regionali. I Numeri del cancro in Italia 2018. Versione per pazienti e cittadini a cura di Fondazione AIOM. Via Malta 12/B – 25124 Brescia. Istituto Superiore di Sanitа. URL: https://www.aiom.it/wp content/uploads/2018/10/2018NumeriCancro-operatori.pdf.
8. Khan S. A., Emadossadaty S., and Ladep N. G. Rising trends in cholangiocarcinoma: is the ICD classifica-tion system misleading us. Journal of Hepatology. 2012; 56 (4): 848-854.
9. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of choles-tatic liver diseases. Journal of Hepatology. 2009; 51 (2): 237-267.
10. Sierra H., Cordova M., Chen C. J., Rajadhyaksha M. Confocal imaging-guided laser ablation of basal cell carcinomas: an ex vivo study. Journal of Investigative Dermatology. 2015; 135 (2): 612-615.
11. Storozhakov G. I., Fedorov I. G., Chichkina M. A., Kosjura S. D., Il'chenko L. Ju. A case of nonspecific ul-cerative colitis complicated by the development of colon cancer and Klatskin's tumor. Dokazatel'naya gastroenter-ologiya = Russian Journal of Evidence-Based Gastroenterology. 2014; 3 (1): 38-42. (In Russ.).
12. Patel A. H., Harnois D. M., Klee G. G., LaRusso N. F., Gores G. J. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing сholangitis. American Journal of Gastroenterology. 2000; 95 (1): 204-207.
13. Levy C., Lymp J., Angulo P., Gores G. J., Larusso N., Lindor K. D. The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Digestive Diseases and Sciences. 2005; 50 (9):
14. -1740.
15. Sinakos E., Saenger A. K., Keach J., Kim W. R., Lindor K. D. Many patients with primary sclerosing cholan-gitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma. Clinical Gastroenterology and Hepatology. 2011; 9(5): p. 434-439.
16. Masselli G., Manfredi R., Vecchioli A., Gualdi G. MR imaging and MR cholangiopancreatography in the preoperative evaluation of hilar cholangiocarcinoma: correlation with surgical and pathologic findings. European Journal of Radiology. 2008; 18(10): 2213-2221.
17. Moon C. M., Bang S., Chung J. B., Seung W. P., Si Y. S., Mijin Y., Jong D. L. Usefulness of 18F-fluorodeoxyglucose positron emission tomography in differential diagnosis and staging of cholangiocarcinomas. Jour-nal of Gastroenterology and Hepatology. 2008; 23 (5): 759-765.
18. Lee J., Park S. H., Chang H. M., Kim J. S., Choi H. J., Lee M. A., Jang J. S., Jeung H. C., Kang J. H., Lee H. W., Shin D. B., Kang H. J., Sun J.-M., Park J. O., Park Y. S., Kang W. K., Lim H. Y. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. The Lancet Oncology. 2012; 13 (2): 181-188.
19. Boehm L. M., Jayakrishnan T. T., Miura J. T., Zacharias A. J., Johnston F. M., Turaga K. K., Gamblin T. C. Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. Journal of Surgical Oncology. 2015; 111 (2): 213-220.
20. Ajith K. Siriwardena. Klatskin Tumor. Journal of Clinical Oncology. 2017; 35 (36): 4091-4092.
21. Desai H., Gondalia R., Suhocki P. Percutaneous Hepaticojejunostomy across an Isolated Bile Duct after Klatskin Tumor Resection. Journal of Vascular and Interventional Radiology. 2019; 30 (8): 1242-1243.
22. Kozlov A. V., Tarazov P. G., Polikarpov A. A., Moiseenko A. V., Urbanskij A. I., Jutkin M. V., Jakshieva G. M., Granov D. A. Antegrade endobiliary forceps biopsy improves diagnosis of Klatskin tumor compared to brush biop-sy. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatolo-gy, Coloproctology. 2022; 32 (2): 45-54. (In Russ.).
23. Endo I., Gonen M., Yopp A. C., Dalal K. M., Zhou Q., Klimstra D., D'Angelica M., DeMatteo R. P., Fong Y., Schwartz L., Kemeny N., O'Reilly E., Abou-Alfa G. K., Shimada H., Blumgart L. H., Jarnagin W. R. Intrahepatic chol-angiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Annals of Surgery. 2008; 248 (1): 84-96.
24. Cambridge W. A., Fairfield C., Powell J. J., Harrison E. M., Søreide K., Wigmore S. J., Guest R. V. Meta-analysis and Meta-regression of Survival After Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma. Annals of Surgery: 2021; 273 (2): 240-250.
Review
For citations:
Dedov A.V., Mustafin R.D., Polukhina E.A. About the difficuties of the diagnostics and treament of the Klatskin`s tumour. Astrakhan medical journal. 2023;18(2):110–119. (In Russ.) https://doi.org/10.29039/1992-6499-2023-2-110-119
Views:
236
Email this article 